Simplex Trading’s Aimmune Therapeutics AIMT Stock Holding History

Simplex Trading’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-200	Closed	-$3.4K	–	8751
2020 Q1	$2K	Sell	200 -31,562	-99%	-$807K	﹤0.01%	7287
2019 Q4	$1.06M	Buy	31,762 +15,030	+90%	+$420K	﹤0.01%	2039
2019 Q3	$350K	Buy	+16,732	New	+$342K	﹤0.01%	3011
2018 Q4	–	Sell	-3,800	Closed	-$98.3K	–	8217
2018 Q3	$103K	Sell	3,800 -5,811	-60%	-$164K	﹤0.01%	4407
2018 Q2	$258K	Sell	9,611 -22,497	-70%	-$689K	﹤0.01%	3192
2018 Q1	$1.02M	Buy	32,108 +31,288	+3,816%	+$1.1M	0.04%	390
2017 Q4	$31K	Buy	+820	New	+$26.5K	﹤0.01%	2909
2017 Q3	–	Sell	-315	Closed	-$6.79K	–	6987
2017 Q2	$6K	Buy	+315	New	+$6.01K	﹤0.01%	4506
2016 Q4	–	Sell	-1,608	Closed	-$24K	–	6832
2016 Q3	$24K	Buy	+1,608	New	+$21.7K	﹤0.01%	2814

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Simplex Trading's AIMT Position: Q2 2020 in Review

Simplex Trading sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 200 shares — an estimated $3.4K sold.

Simplex Trading first reported a position in AIMT in Q3 2016 and held it in 9 quarters. The position peaked at $1.06M in Q4 2019. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

Simplex Trading reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
Simplex Trading sold 200 Aimmune Therapeutics shares in Q2 2020, an estimated $3.4K.
Simplex Trading first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 9 quarters.
Simplex Trading's Aimmune Therapeutics position peaked at $1.06M in Q4 2019.
165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Simplex Trading's 13F filing for Q2 2020, filed 13 Jul 2020.